Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparable efficacy and safety of BK0023 vs filgrastim (Neupogen) in chemotherapy-induced neutropenia in women with breast cancer
2007-007161-20Phase 3Active
- Sponsor
- BIO-KER SRL
- Start
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Neukast in chemotherapy-induced neutropenia (CIN) and neutropenia (2 arms), sponsored by BIO-KER SRL. Primary endpoint: Duration of grade 4 neutropenia in first chemotherapy cycle. Started Dec 2008; status: active.
02
Drugs
Neukast
03
Conditions
chemotherapy-induced neutropenia (CIN)neutropenia
Beyond the preview
Go deeper on 2007-007161-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007161-20.